Home  >  Products  >  CFI (complement factor I ) Blocking Peptide (the N terminal of CFI)(100ug)
CFI (complement factor I ) Blocking Peptide (the N terminal of CFI)(100ug)

CFI (complement factor I ) Blocking Peptide (the N terminal of CFI)(100ug)

Supplier: Aviva Systems Biology Incorporated
Star_fadedStar_fadedStar_fadedStar_fadedStar_faded
0 reviews | Write a Review Pencil
This is a synthetic peptide designed for use in combination with anti-CFI Antibody (ARP63227_P050), made by Aviva Systems Biology. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications. Please inquire for more details.
Reactivities: Human
Presku: AAP63227
Size: 100ug
Weight: 64kDa
Gene: The peptide is characterized by mass spectroscopy
Format: Lyophilized powder
Target: This gene encodes a serine proteinase that is essential for regulating the complement cascade. The encoded preproprotein is cleaved to produce both heavy and light chains, which are linked by disulfide bonds to form a heterodimeric glycoprotein. This heterodimer can cleave and inactivate the complement components C4b and C3b, and it prevents the assembly of the C3 and C5 convertase enzymes. Defects in this gene cause complement factor I deficiency, an autosomal recessive disease associated with a susceptibility to pyogenic infections. Mutations in this gene have been associated with a predisposition to atypical hemolytic uraemic syndrome, a disease characterized by acute renal failure, microangiopathic hemolytic anemia and thrombocytopenia. Primary glomerulonephritis with immmune deposits is another condition associated with mutation of this gene.
Alternative names: AHUS3; C3BINA; C3b-INA; FI; IF; KAF
See Full Product Listings >